The Cancer Research UK Cambridge Centre has become the first UK institute to be designated a Comprehensive Cancer Center of Excellence by the European Academy of Cancer Sciences (EACS).
Kate Gross was just 36 years old when she died of cancer. Researchers at Cambridge – including her husband – are trying to ensure that others receive their diagnoses early enough to stop their cancer.
Scientists have created mini biological models of human primary liver cancers, known as organoids, in the lab for the first time. In a paper published in Nature Medicine, the tiny laboratory models of tumours were used to identify a new drug that could potentially treat certain types of liver cancer.
Professor Greg Hannon is today announced as the new director of the Cancer Research UK Cambridge Institute.
Seventy-two new genetic variants that contribute to the risk of developing breast cancer have been identified by a major international collaboration involving hundreds of researchers worldwide.
In the centenary year of the publication of a seminal treatise on the physical and mathematical principles underpinning nature – On Growth and Form by D’Arcy Wentworth Thompson – a Cambridge physicist has led a study describing an elegantly simple solution to a puzzle that has taxed biologists for centuries: how complex branching patterns of tissues arise.
Scientists at the University of Cambridge have developed a new statistical model which estimates kidney function in patients with cancer. This is the most accurate model for estimating kidney function yet developed and should help cancer specialists treat their patients more safely and improve the accuracy of chemotherapy dosing. The model is now available free online.
Family history and location of genetic fault affect risk for carriers of key breast and ovarian cancer genes20 Jun 2017
A large scale study of women carrying faults in important cancer genes should enable doctors to provide better advice and counselling for treatments and lifestyle changes aimed at reducing this risk.
Cambridge-based start-up company Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.